See more : Tiga Acquisition Corp. (TINV-UN) Income Statement Analysis – Financial Results
Complete financial analysis of XBiotech Inc. (XBIT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of XBiotech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Golden Ocean Group Limited (GOGL.OL) Income Statement Analysis – Financial Results
- 1&1 AG (1U1.DE) Income Statement Analysis – Financial Results
- Focus Entertainment Société anonyme (ALFOC.PA) Income Statement Analysis – Financial Results
- W.R. Berkley Corporation 5.10% (WRB-PF) Income Statement Analysis – Financial Results
- Electro Optic Systems Holdings Limited (EOS.AX) Income Statement Analysis – Financial Results
XBiotech Inc. (XBIT)
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 4.01M | 18.39M | 44.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 651.00K | 5.82M | 34.55M | 2.36M | 2.43M | 1.48M | 698.00K | 699.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.74M | 3.36M | 12.57M | 9.45M | -2.36M | -2.43M | -1.48M | -698.00K | -699.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 83.77% | 68.36% | 21.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.85M | 31.54M | 28.27M | 9.53M | 24.09M | 15.73M | 26.42M | 42.49M | 31.31M | 14.33M | 7.94M | 13.33M |
| General & Administrative | 4.66M | 6.31M | 9.39M | 18.20M | 7.14M | 5.27M | 7.64M | 10.28M | 6.20M | 7.45M | 1.99M | 1.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.66M | 6.31M | 9.39M | 18.20M | 7.14M | 5.27M | 7.64M | 10.28M | 6.20M | 7.45M | 1.99M | 1.83M |
| Other Expenses | 0.00 | -121.00K | -132.00K | -503.00K | 750.01M | 4.00K | 0.00 | 0.00 | 21.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.51M | 37.85M | 37.66M | 27.73M | 31.23M | 20.99M | 34.06M | 52.76M | 37.51M | 21.78M | 9.93M | 15.16M |
| Cost & Expenses | 37.51M | 38.50M | 43.48M | 62.27M | 31.23M | 20.99M | 34.06M | 52.76M | 37.51M | 21.78M | 9.93M | 15.16M |
| Interest Income | 10.42M | 3.82M | 467.00K | 2.46M | 564.00K | 400.00K | 354.00K | 49.00K | 0.00 | 1.00K | 0.00 | 3.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.74M | 2.61M | 2.65M | 2.24M | 2.36M | 2.43M | 1.48M | 698.00K | 699.00K | 664.00K | 784.00K | 946.00K |
| EBITDA | -35.77M | -31.88M | -22.43M | -16.04M | -28.87M | -18.71M | -32.58M | -52.06M | -36.81M | -21.11M | -9.14M | -14.21M |
| EBITDA Ratio | 0.00% | -725.09% | -118.10% | -44.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.51M | -34.49M | -25.08M | -18.28M | -31.23M | -20.99M | -34.06M | -52.76M | -37.51M | -21.78M | -9.93M | -15.16M |
| Operating Income Ratio | 0.00% | -860.10% | -136.36% | -41.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.20M | 902.00K | -376.00K | 5.45M | 749.69M | -144.00K | 909.00K | 2.00K | 27.00K | 54.00K | -2.00K | 3.00K |
| Income Before Tax | -24.31M | -33.59M | -25.46M | -12.83M | 718.45M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Income Before Tax Ratio | 0.00% | -837.61% | -138.40% | -29.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 244.00K | -688.00K | -8.04M | -1.61M | 49.82M | -144.00K | -909.00K | -2.00K | -6.00K | -54.00K | 2.00K | 0.00 |
| Net Income | -24.56M | -32.90M | -17.41M | -11.22M | 668.63M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Net Income Ratio | 0.00% | -820.45% | -94.67% | -25.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.81 | -1.08 | -0.58 | -0.36 | 17.17 | -0.59 | -0.95 | -1.63 | -1.22 | -0.68 | -0.31 | -0.48 |
| EPS Diluted | -0.81 | -1.08 | -0.58 | -0.36 | 14.44 | -0.59 | -0.95 | -1.63 | -1.22 | -0.68 | -0.31 | -0.48 |
| Weighted Avg Shares Out | 30.32M | 30.44M | 30.04M | 30.82M | 38.95M | 35.80M | 34.88M | 32.40M | 30.80M | 31.72M | 31.72M | 31.72M |
| Weighted Avg Shares Out (Dil) | 30.44M | 30.44M | 30.04M | 30.82M | 46.32M | 35.80M | 34.88M | 32.40M | 30.80M | 31.72M | 31.72M | 31.72M |
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
Tuesday, XBiotech Inc XBIT announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer.
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy
XBiotech: Several Shots On Goal In Big Target Market Indications
XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke. Other studies being deployed are Natrunix for the treatment of patients with pancreatic cancer and rheumatoid arthritis. While other biologics...
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
Two microcap biotech stocks to consider for the science-challenged among us.
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin...
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
(Phase II Multicenter Study is Proceeding Well with High Anticipation) (Phase II Multicenter Study is Proceeding Well with High Anticipation)
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose...
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic...
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key...
Why Are XBiotech Shares Trading Higher Today
The French authority has signed off XBiotech Inc's (NASDAQ: XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs.
Source: https://incomestatements.info
Category: Stock Reports